MY129751A - New dihydropteridinones, processes for preparing them and their use as medicaments. - Google Patents

New dihydropteridinones, processes for preparing them and their use as medicaments.

Info

Publication number
MY129751A
MY129751A MYPI20023275A MYPI20023275A MY129751A MY 129751 A MY129751 A MY 129751A MY PI20023275 A MYPI20023275 A MY PI20023275A MY PI20023275 A MYPI20023275 A MY PI20023275A MY 129751 A MY129751 A MY 129751A
Authority
MY
Malaysia
Prior art keywords
preparing
processes
medicaments
dihydropteridinones
new
Prior art date
Application number
MYPI20023275A
Inventor
Eckhart Bauer
Gisela Schnapp
Martin Steegmaier
Steffen Breitfelder
Christian Eickmeier
Mattias Grauert
Matthias Hoffmann
Thorsten Lehmann-Lintz
Gerald Pohl
Jens Quant
Norbert Redemann
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MY129751A publication Critical patent/MY129751A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

THE PRESENT INVENTION RELATES TO NEW DIHYDROPTERIDINONES OF GENERAL FORMULA (I) WHEREIN THE GROUPS X, R¹,R²,R³,R⁴,R5, AND R7 HAVE THE MEANINGS GIVEN IN THE CLAIMS AND SPECIFICATION, THE ISOMERS THEREOF, PROCESSES FOR PREPARING THESE DIHYDROPTERIDINONES AS WELL AS THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS.
MYPI20023275A 2001-09-04 2002-09-02 New dihydropteridinones, processes for preparing them and their use as medicaments. MY129751A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10143272 2001-09-04

Publications (1)

Publication Number Publication Date
MY129751A true MY129751A (en) 2007-04-30

Family

ID=7697637

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20023275A MY129751A (en) 2001-09-04 2002-09-02 New dihydropteridinones, processes for preparing them and their use as medicaments.

Country Status (30)

Country Link
EP (1) EP1427730B1 (en)
JP (1) JP3876254B2 (en)
KR (1) KR100955589B1 (en)
CN (1) CN1551881A (en)
AR (1) AR036586A1 (en)
AT (1) ATE332898T1 (en)
AU (1) AU2002337047B2 (en)
BR (1) BRPI0212137A2 (en)
CA (1) CA2458699C (en)
CO (1) CO5560575A2 (en)
CY (1) CY1105337T1 (en)
DE (1) DE50207522D1 (en)
DK (1) DK1427730T3 (en)
EA (1) EA007062B1 (en)
EC (1) ECSP045003A (en)
ES (1) ES2268093T3 (en)
HR (1) HRP20040213A2 (en)
HU (1) HUP0401293A3 (en)
IL (2) IL160440A0 (en)
MX (1) MXPA04002067A (en)
MY (1) MY129751A (en)
NO (1) NO328804B1 (en)
NZ (1) NZ531928A (en)
PL (1) PL369740A1 (en)
PT (1) PT1427730E (en)
RS (1) RS51012B (en)
UA (1) UA76512C2 (en)
UY (1) UY27427A1 (en)
WO (1) WO2003020722A1 (en)
ZA (1) ZA200401365B (en)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
NZ516610A (en) 1999-08-04 2004-05-28 Icagen Inc Benzanilides as potassium channel openers
BR0318145A (en) * 2003-02-26 2006-02-21 Boehringer Ingelheim Pharma dihydropteridinones, processes for their preparation and their application as a medicine
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004029784A1 (en) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
DE102004033670A1 (en) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pyridodihydropyrazinone, process for its preparation and its use as a medicament
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1630163A1 (en) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, methods for their preparation and their use as drugs
EP1632493A1 (en) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridine derivatives, methods for their preparation and their use as drugs
JP2008510771A (en) * 2004-08-27 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dihydropteridinone, process for its preparation and its use as a pharmaceutical agent
DE102004058337A1 (en) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of fused piperazin-2-one derivatives
WO2007014838A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
TW200804389A (en) 2006-02-14 2008-01-16 Vertex Pharma Dihydrodiazepines useful as inhibitors of protein kinases
EP2029599A1 (en) * 2006-05-19 2009-03-04 Astra Zeneca AB Dihydropteridine compounds as anti proliferative agents
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
WO2008009909A1 (en) * 2006-07-17 2008-01-24 Astrazeneca Ab Pteridimones as modulators of polo-like kinase
WO2008040951A1 (en) * 2006-10-03 2008-04-10 Astrazeneca Ab Compounds
ATE543819T1 (en) * 2006-10-19 2012-02-15 Signal Pharm Llc HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF AND TREATMENT METHODS THEREOF
EP1953163A1 (en) * 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinone derivatives as PI3-kinases inhibitors
WO2008113711A1 (en) 2007-03-22 2008-09-25 F. Hoffmann-La Roche Ag Substituted pyrimidodiazepines useful as plk1 inhibitors
WO2008157235A1 (en) * 2007-06-13 2008-12-24 University Of Virginia Patent Foundation Rsk inhibitors as anti-septicemia agents
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
CA2695753A1 (en) * 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinases inhibitors
WO2009042711A1 (en) 2007-09-25 2009-04-02 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
JP5400791B2 (en) * 2007-12-04 2014-01-29 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Substituted dihydropteridin-6-one derivatives, processes for their preparation and their use as kinase inhibitors
JP5593234B2 (en) 2008-03-11 2014-09-17 ユニバーシティー ヘルス ネットワーク Methods of treating cancer using neuropeptide Y5R (NPY5R) antagonists
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
GB0807452D0 (en) * 2008-04-24 2008-05-28 Chroma Therapeutics Ltd PLK inhibitors
US8093043B2 (en) 2008-06-04 2012-01-10 New York University β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
JP2011527667A (en) 2008-06-18 2011-11-04 武田薬品工業株式会社 Halo-substituted pyrimidodiazepine
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
ES2467108T3 (en) 2008-12-09 2014-06-11 Gilead Sciences, Inc. Toll type receiver modulators
NO2477987T3 (en) 2009-09-14 2018-06-09
CN102020643A (en) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 dihydropteridine ketone derivative, and preparation method and medicinal application thereof
SG179206A1 (en) 2009-09-25 2012-04-27 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
CA2773827A1 (en) 2009-09-25 2011-03-31 Vertex Pharmaceuticals Incorporated Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
MY177695A (en) 2009-10-26 2020-09-23 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
US8541418B2 (en) 2009-12-23 2013-09-24 Elan Pharmaceutical, Inc. Inhibitors of polo-like kinase
EP2536725B1 (en) 2010-02-17 2015-10-28 Boehringer Ingelheim International GmbH Dihydropteridinones, method for production and use thereof
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
KR101978537B1 (en) 2011-10-19 2019-05-14 시그날 파마소티칼 엘엘씨 Treatment of cancer with tor kinase inhibitors
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc METHYLATION MODIFICATION ENZYME MODULATORS, COMPOSITIONS AND USES THEREOF
EP2780013A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc METHYLATION MODIFICATION ENZYME MODULATORS, COMPOSITIONS AND USES THEREOF
JP6076370B2 (en) 2011-12-02 2017-02-08 シグナル ファーマシューティカルズ，エルエルシー 7- (6- (2-Hydroxypropan-2-yl) pyridin-3-yl) -1-((trans) -4-methoxycyclohexyl) -3,4-dihydropyrazino [2,3-b] pyrazine-2 Pharmaceutical composition of (1H) -one, its solid form, and method of use
NZ628762A (en) 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
US8865716B2 (en) 2012-02-23 2014-10-21 Boehringer Ingelheim International Gmbh Dihydropteridinones II
US9006226B2 (en) 2012-02-23 2015-04-14 Boehringer Ingelheim International Gmbh Dihydropteridinones I
TWI615143B (en) 2012-02-24 2018-02-21 標誌製藥公司 Methods for treating cancer using tor kinase inhibitor combination therapy
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP2945636B1 (en) 2013-01-16 2017-06-28 Signal Pharmaceuticals, LLC Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
EP2958918B1 (en) * 2013-02-21 2016-12-07 Boehringer Ingelheim International GmbH Dihydropteridinones ii
JP6052527B2 (en) * 2013-02-21 2016-12-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dihydropteridinone I
WO2014151142A1 (en) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
TW201521725A (en) 2013-04-17 2015-06-16 Signal Pharm Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
US9937169B2 (en) 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
BR112015026297B1 (en) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc USE OF A TOR KINASE INHIBITOR AND 5-SUBSTITUTED QUINAZOLINONE, PHARMACEUTICAL COMPOSITION THAT COMPRISES THEM, AND KIT
TW201527300A (en) 2013-04-17 2015-07-16 Signal Pharm Llc About 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyridinium[2 , 3-b]pyridin-2 (1H)-ketone pharmaceutical formulation, method, solid state type and use method
AU2014254052B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
BR112015026292B1 (en) 2013-04-17 2022-04-12 Signal Pharmaceuticals, Llc USE OF 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOLE-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO [2,3-B]PYRAZIN -2(1H)- ONA AND IN VITRO METHODS
US9782427B2 (en) 2013-04-17 2017-10-10 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
EP3003313A1 (en) 2013-05-29 2016-04-13 Signal Pharmaceuticals, LLC Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
HK1221721A1 (en) * 2013-07-09 2017-06-09 Bayer Pharma Aktiengesellschaft Modified bet-protein-inhibiting dihydroquinoxalinones and dihydropyridopyrazinones
AU2014292888B2 (en) 2013-07-25 2018-03-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
CN103664845B (en) * 2013-12-27 2016-02-10 湖南欧亚生物有限公司 The preparation method of amino-2, the 3-Dihydrobenzofuranes-4-formic acid of a kind of Plk kinase inhibitor drug intermediate 7-
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015193229A1 (en) * 2014-06-19 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-protein inhibiting 1,4-dihydropyrido[3,4-b]pyrazinones with meta-substituted aromatic amino- or ether groups
WO2015193228A1 (en) * 2014-06-19 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-protein inhibiting 1,4-dihydropyrido[3,4-b]pyrazinones with para-substituted aromatic amino- or ether groups
PT3166607T (en) 2014-07-11 2022-12-07 Gilead Sciences Inc Modulators of toll-like receptors for the treatment of hiv
EA201790189A1 (en) 2014-07-14 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи METHODS OF TREATING MALIGNANT NUMER FORMATION USING SUBSTITUTED PYRROPYRYMIDIN COMPOUNDS, COMPOSITIONS ON THEIR BASIS
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
CN106715437A (en) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 Diazepane derivatives and uses thereof
BR112017005100A2 (en) 2014-09-16 2017-12-05 Gilead Sciences Inc Methods of Preparation of Toll-like Receptor Modulators
CA2960436C (en) 2014-09-16 2021-01-05 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
JP6815318B2 (en) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド How to Induce Targeted Proteolysis by Bifunctional Molecules
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
RU2018112953A (en) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. ACETAMIDTIENOTRIAZOLODIAZODEPINE AND WAYS OF THEIR APPLICATION
HK1256417A1 (en) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 Cyano thienotriazolodiazepines and uses thereof
MX2018006499A (en) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibtors and uses thereof.
DE102017005091A1 (en) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituted 3,4-dihydropyrido [2,3-b] pyrazine-2 (1H) -one
DE102017005089A1 (en) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituted 3,4-dihydroquinoxaline-2 (1H) -one
US10457640B2 (en) 2016-10-19 2019-10-29 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of EZH2
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
AU2018392805A1 (en) * 2017-12-22 2020-05-07 Dana-Farber Cancer Institute, Inc. NEK inhibitors and methods of use
ES2969982T3 (en) * 2018-04-24 2024-05-23 Vertex Pharma Pteridinone compounds and uses thereof
CN108610343A (en) * 2018-06-12 2018-10-02 杨文思 A kind of epidermal growth factor receptor inhibitor and its synthetic method for treating cancer
EP3833353A4 (en) * 2018-08-10 2022-08-24 Yale University SMALL MOLECULAR PI5P4K ALPHA/BETA INHIBITORS AND METHODS OF TREATMENT THEREOF
CN111039944B (en) 2018-10-12 2021-11-23 中国科学院合肥物质科学研究院 MST1 kinase inhibitors and uses thereof
CN113637017B (en) * 2021-08-12 2024-03-26 中国药科大学 Compound containing dihydropterin structure, its preparation method and application

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2645152B1 (en) * 1989-03-30 1991-05-31 Lipha 3H-PTERIDINONES-4, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM
CA2029651C (en) * 1989-11-17 2000-06-06 David D. Davey Tricyclic pteridinones and a process for their preparation
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
EP1409487A1 (en) * 1999-09-15 2004-04-21 Warner-Lambert Company Llc Pteridinones as kinase inhibitors
WO2002076954A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases

Also Published As

Publication number Publication date
EP1427730B1 (en) 2006-07-12
NZ531928A (en) 2005-10-28
MXPA04002067A (en) 2004-06-07
NO20040680L (en) 2004-02-16
AR036586A1 (en) 2004-09-22
CA2458699A1 (en) 2003-03-13
AU2002337047B8 (en) 2003-03-18
IL160440A0 (en) 2004-07-25
UY27427A1 (en) 2003-03-31
CO5560575A2 (en) 2005-09-30
YU27304A (en) 2006-08-17
CN1551881A (en) 2004-12-01
EA200400368A1 (en) 2004-12-30
IL160440A (en) 2009-09-01
ATE332898T1 (en) 2006-08-15
KR100955589B1 (en) 2010-04-30
HRP20040213A2 (en) 2005-02-28
ZA200401365B (en) 2005-05-27
PT1427730E (en) 2006-11-30
ECSP045003A (en) 2004-04-28
WO2003020722A1 (en) 2003-03-13
ES2268093T3 (en) 2007-03-16
JP2005501904A (en) 2005-01-20
CY1105337T1 (en) 2010-03-03
HUP0401293A2 (en) 2004-10-28
NO328804B1 (en) 2010-05-18
RS51012B (en) 2010-10-31
KR20040029465A (en) 2004-04-06
UA76512C2 (en) 2006-08-15
PL369740A1 (en) 2005-05-02
DE50207522D1 (en) 2006-08-24
EP1427730A1 (en) 2004-06-16
AU2002337047B2 (en) 2008-01-10
CA2458699C (en) 2010-10-19
BRPI0212137A2 (en) 2016-06-28
HUP0401293A3 (en) 2008-03-28
JP3876254B2 (en) 2007-01-31
DK1427730T3 (en) 2006-11-06
NO20040680D0 (en) 2004-02-16
EA007062B1 (en) 2006-06-30

Similar Documents

Publication Publication Date Title
MY129751A (en) New dihydropteridinones, processes for preparing them and their use as medicaments.
NO20026064D0 (en) New connections
MY128924A (en) Novel compounds
SE0202133D0 (en) Novel compounds
NO20023933D0 (en) New connections
SE0104140D0 (en) Novel Compounds
SE0200920D0 (en) Novel compounds
SE0300480D0 (en) Novel compounds
TW200621777A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
SE0103836D0 (en) Novel compounds
SE9902987D0 (en) Novel compounds
GB0003154D0 (en) Novel compounds
MY127144A (en) New anticholinergics which may be used as medicaments as well as processes for preparing them
MY144903A (en) Pyrrolopyridine derivatives and their use as crth2 antagonists
MY140693A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
MXPA04000756A (en) Novel compounds.
SE0302116D0 (en) Novel compounds
SE0302139D0 (en) Novel compounds
SE0300119D0 (en) Novel compounds
MY145613A (en) Novel compounds
TW200604197A (en) New compounds
MY141583A (en) Novel fused heterocycles and uses thereof
MY143353A (en) Diazole derivatives
SE0101038D0 (en) Novel compounds
SE0300091D0 (en) Novel compounds